These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22440241)

  • 1. Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy.
    Berardi R; Maccaroni E; Mandolesi A; Mantello G; Onofri A; Biscotti T; Pierantoni C; Siquini W; Marmorale C; Guerrieri M; Bearzi I; Cascinu S
    Dig Liver Dis; 2012 Jul; 44(7):617-22. PubMed ID: 22440241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
    Voboril R; Rychterova V; Voborilova J; Kubecova M; Fanta J; Dvorak J
    Neoplasma; 2016; 63(3):462-70. PubMed ID: 26952512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo adjuvant chemo-radiotherapy and rectal cancer: can India follow the West?
    Bansal V; Bhutani R; Doval D; Kumar K; Pande P; Kumar G
    J Cancer Res Ther; 2012; 8(2):209-14. PubMed ID: 22842363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
    Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
    Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of nuclear factor κ B expression in patients with advanced cervical cancer undergoing radiation therapy followed by hysterectomy.
    Baiocchi G; Begnami MD; Fukazawa EM; Oliveira RA; Faloppa CC; Kumagai LY; Badiglian-Filho L; Pellizzon AC; Maia MA; Jacinto AA; Soares FA; Lopes A
    J Clin Pathol; 2012 Jul; 65(7):614-8. PubMed ID: 22447917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome.
    Berardi R; Mantello G; Scartozzi M; Del Prete S; Luppi G; Martinelli R; Fumagalli M; Grillo-Ruggieri F; Bearzi I; Mandolesi A; Marmorale C; Cascinu S
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1437-43. PubMed ID: 19386440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
    Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
    Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy rather than neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer with high tumor burden.
    Koca D; Oztop J; Yilmaz U
    Hepatogastroenterology; 2012 Oct; 59(119):2151-4. PubMed ID: 22440247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
    Qiu HZ; Wu B; Xiao Y; Lin GL
    Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
    Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
    Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy.
    Giralt J; Navalpotro B; Hermosilla E; de Torres I; Espin E; Reyes V; Cerezo L; de las Heras M; Ramon y Cajal S; Armengol M; Benavente S
    Oncology; 2006; 71(5-6):312-9. PubMed ID: 17687192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
    Read TE; Andujar JE; Caushaj PF; Johnston DR; Dietz DW; Myerson RJ; Fleshman JW; Birnbaum EH; Mutch MG; Kodner IJ
    Dis Colon Rectum; 2004 Jun; 47(6):825-31. PubMed ID: 15108025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer.
    Palmer G; Martling A; Cedermark B; Holm T
    Colorectal Dis; 2011 Dec; 13(12):1361-9. PubMed ID: 20958913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
    Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
    J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.